Study of Different Heterocycles Showing Significant Anti-severe Acute Respiratory Syndrome 2 Activity and

Overview

Journal Vet World

Specialty Veterinary Medicine

Date 2024 Jul 30

PMID 39077461

Authors

Aleksandr Yengoyan

Tiruhi Gomktsyan

Vergush Pivazyan

Emma Ghazaryan

Roza Shainova

Armen Karapetyan

Diana Avetyan

Levon Aslanyan

Karine Baroyan

Alexander Tuzikov

Mariam Sargsyan

Bagrat Baghdasaryan

Nane Bayramyan

Sona Hakobyan

Arpine Poghosyan

Aida Avetisyan

Hranush Avagyan

Lina Hakobyan

Karalyan Zaven

Affiliations

Soon will be listed here.

Abstract

Background And Aim: With the emergence of severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), antiviral drug development has gained increased significance due to the high incidence and potentially severe complications of the resulting coronavirus infection. Heterocycle compounds, acting as antimetabolites of DNA and RNA monomers, rank among the most effective antiviral drugs. These compounds' antiviral effects on various SARS-CoV-2 isolates, as found in existing data collections, form the basis for further research. The aim of this study was to examine the possible antiviral effect of some originally synthesized heterocyclic compounds.

Materials And Methods: The main methods were cell culturing, cytotoxicity assay, qRT-PCR assay, tissue and blood cells analysis, and micro-computed tomography (micro-CT) imaging.

Results: In both and conditions, the elimination of SARS-Cov-2 occurred significantly earlier after administration of the compounds compared to the control group. In hamsters, the primary symptoms of coronavirus disease disappeared following administration of heterocycle compounds.

Conclusion: Using delta and omicron strains of the SARS-CoV-2 virus, newly created heterocycle compound analogs dramatically reduced SARS-CoV-2 multiplication, resulting in a drop in viral RNA load in the supernatant under in vitro conditions. Improvements in pathological manifestations in the blood, bone marrow, and internal organs of hamsters demonstrated that heterocycle compounds inhibited SARS-CoV-2 replication both and .

References

Sochacka-Cwikla A, Regiec A, Zimecki M, Artym J, Zaczynska E, Kocieba M . Synthesis and Biological Activity of New 7-Amino-oxazolo[5,4-]Pyrimidine Derivatives. Molecules. 2020; 25(15). PMC: 7436121. DOI: 10.3390/molecules25153558. View

Baeeri M, Foroumadi A, Motamedi M, Yahya-Meymandi A, Firoozpour L, Ostad S . Safety and efficacy of new 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine analogs as potential phosphodiesterase-4 inhibitors in NIH-3T3 mouse fibroblastic cells. Chem Biol Drug Des. 2011; 78(3):438-44. DOI: 10.1111/j.1747-0285.2011.01167.x. View

Todt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha P . In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016; 65(10):1733-43. PMC: 5036239. DOI: 10.1136/gutjnl-2015-311000. View

Ghanbari R, Teimoori A, Sadeghi A, Mohamadkhani A, Rezasoltani S, Asadi E . Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol. 2021; 15:1747-1758. PMC: 7789744. DOI: 10.2217/fmb-2020-0120. View

Sheahan T, Sims A, Zhou S, Graham R, Pruijssers A, Agostini M . An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020; 12(541). PMC: 7164393. DOI: 10.1126/scitranslmed.abb5883. View

Li G, De Clercq E . Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3):149-150. DOI: 10.1038/d41573-020-00016-0. View

Elfiky A . Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020; 253:117592. PMC: 7102646. DOI: 10.1016/j.lfs.2020.117592. View

Li Y, Yang B, Quan Y, Li Z . Advancement of Prodrug Approaches for Nucleotide Antiviral Agents. Curr Top Med Chem. 2021; 21(32):2909-2927. DOI: 10.2174/1568026621666210728094019. View

Dyminska L, Hanuza J, Janczak J, Ptak M, Lisiecki R . Spectroscopic and optical properties of 1,2,4-triazolo[4,3-a]pyridin-3(2H)-one as a component of herbicides. Spectrochim Acta A Mol Biomol Spectrosc. 2023; 303:123141. DOI: 10.1016/j.saa.2023.123141. View

10.

Johnson K, Dangerfield T . Mechanisms of inhibition of viral RNA replication by nucleotide analogs. Enzymes. 2021; 49:39-62. PMC: 8474024. DOI: 10.1016/bs.enz.2021.07.001. View

11.

Negi M, Chawla P, Faruk A, Chawla V . Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic. Bioorg Chem. 2020; 104:104315. PMC: 7513919. DOI: 10.1016/j.bioorg.2020.104315. View

12.

Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M . Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo. 2020; 34(3 Suppl):1597-1602. PMC: 8378021. DOI: 10.21873/invivo.11949. View

13.

Federico S, Margiotta E, Salmaso V, Pastorin G, Kachler S, Klotz K . [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A adenosine receptor subtype. Eur J Med Chem. 2018; 157:837-851. DOI: 10.1016/j.ejmech.2018.08.042. View

14.

Pearson J, Trcka D, Lu S, Hyduk S, Jen M, Aynaud M . Comparison of SARS-CoV-2 indirect and direct RT-qPCR detection methods. Virol J. 2021; 18(1):99. PMC: 8127261. DOI: 10.1186/s12985-021-01574-4. View

15.

Seley-Radtke K, Yates M . The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res. 2018; 154:66-86. PMC: 6396324. DOI: 10.1016/j.antiviral.2018.04.004. View

16.

Bouchonnet F, Dam E, Mammano F, de Soultrait V, Hennere G, Benech H . Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues. J Virol. 2004; 79(2):812-22. PMC: 538537. DOI: 10.1128/JVI.79.2.812-822.2005. View

17.

Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann P, Nakajima N . Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020; 117(28):16587-16595. PMC: 7368255. DOI: 10.1073/pnas.2009799117. View

18.

Avagyan H, Hakobyan S, Poghosyan A, Hakobyan L, Abroyan L, Karalova E . Severe Acute Respiratory Syndrome Coronavirus-2 Delta Variant Study In Vitro and Vivo. Curr Issues Mol Biol. 2023; 45(1):249-267. PMC: 9857502. DOI: 10.3390/cimb45010019. View

19.

Brussow H . COVID-19: vaccination problems. Environ Microbiol. 2021; 23(6):2878-2890. PMC: 8209888. DOI: 10.1111/1462-2920.15549. View

20.

Sasaki-Tanaka R, Shibata T, Okamoto H, Moriyama M, Kanda T . Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. Int J Mol Sci. 2022; 23(5). PMC: 8910232. DOI: 10.3390/ijms23052631. View